Boston Scientific/Corautus Genetics
This article was originally published in The Gray Sheet
Executive Summary
Phase IIb pivotal trial receives FDA go-ahead to evaluate Vascular Endothelial Growth Factor-2 for treating severe coronary artery disease. Corautus' factor will be delivered through Boston Scientific's Stiletto endocardial direct-injection catheter under a strategic alliance begun in July 2003. The randomized, double-blinded trial, set to commence in Q3, will enroll up to 404 patients in as many as 20 U.S. centers. The study likely will finish by July 2005...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.